Developer docs
API playgroundTry for free, no card

Search company profiles

InspireMD

Full company profile

uuid0003jvt

Namestring
InspireMD
Legal namestring
InspireMD, Inc.
Websiteurl
inspiremd.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

InspireMD is a U.S.-incorporated (Delaware) medical device company headquartered in Miami, Florida, with an Israeli R&D subsidiary, focused on stroke prevention through carotid artery stenting. Its commercial product is the CGuard Prime Carotid Stent System, a dual-layer device combining an inner self-expanding nitinol frame with an outer finely woven polyethylene terephthalate (PET) MicroNet mesh covering approximately 150-180 micrometer pore size, designed to prevent plaque prolapse and embolization during and after carotid artery stenting procedures. The system also incorporates SmartFit, a conformable open-cell stent design intended to adapt to a wide range of anatomies without tapered configurations.

The company's flagship product received FDA premarket approval in June 2025 and was launched in the U.S. market in July 2025, following international commercialization under CE MDR approval. The company is building a pipeline that includes the SwitchGuard Neuro Protection System for transcarotid artery revascularization (TCAR) procedures, currently in the CGUARDIANS III pivotal study, and is pursuing a PMA supplement for its 80 cm stent for the TCAR indication.

InspireMD generates revenue through direct enterprise field sales of its hardware products to hospitals and vascular intervention centers, with go-to-market supplemented by medical conference participation, peer-reviewed clinical publications, and physician education. Customers are vascular surgeons and interventional cardiologists treating patients with carotid artery stenosis who are at high risk for carotid endarterectomy. As of Q1 2026, the company reported revenue of $3.4 million, had raised over $189 million in cumulative funding across multiple private placements and warrant exercises since 2010, and was operating with 51-100 employees.

Short descriptiontext

InspireMD is a Miami-based medical device company that develops and commercializes the CGuard Prime carotid stent system, a MicroNet mesh-covered stent for stroke prevention, selling directly to hospitals and vascular specialists in the U.S. and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
carotid stent systems, stroke prevention devices, embolic protection stents, vascular medical devices, endovascular intervention devices
Industry3 codes
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Vascular Medical Devices (Carotid Stent Systems)
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CGuard Prime Carotid Stent System Sales
TypeHardware Sales
Description

Sale of FDA-approved CGuard Prime carotid stent system and delivery components to hospitals and vascular intervention centers. Revenue generated from product sales to healthcare providers performing carotid artery stenting procedures. Q4 2025 revenue of $3.1M with 62% year-over-year increase driven by U.S. launch and international expansion.

fool.com
2International Product Sales
TypeHardware Sales
Description

Revenue from international markets where CGuard has CE MDR approval. CGuard EPS indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy.

fool.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1CGuard
Description

Next-generation carotid stenting system featuring a unique dual-layer design with a finely woven MicroNet mesh covering for stroke prevention

inspiremd.com
+4 more records
Core offering1 text field

InspireMD develops and commercializes the CGuard Prime Carotid Stent System, a dual-layer carotid stent with proprietary MicroNet mesh technology (woven PET outer layer with ~150-180 μm pore size) over a SmartFit nitinol frame, designed to prevent plaque prolapse and embolization during carotid artery stenting procedures for stroke prevention. The product is sold to hospitals and vascular intervention centers for use in patients at high risk for adverse events from carotid endarterectomy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 0.95% 30-day Death, Stroke, or MI rate - lowest of any pivotal carotid stenting study
+3 more records
Product overview1 text field

InspireMD is a medical device company focused on stroke prevention through carotid artery stenting. The company offers a unified product portfolio centered on the CGuard Prime Carotid Stent System, which incorporates the proprietary MicroNet mesh technology for embolic protection. The flagship product is a dual-layer stent combining SmartFit nitinol frame technology with MicroNet mesh covering. Additional pipeline offerings include the SwitchGuard Neuro Protection System for TCAR procedures, which is currently in clinical development.

Product and service1 record
1CGuard Prime Carotid Stent System
CategoryVascular Medical Devices - Carotid Stent Systems
Description

Dual-layer carotid stent system combining a SmartFit self-expanding nitinol open-cell frame with a MicroNet polyethylene terephthalate (PET) mesh outer covering (~150-180 μm pore size) for stroke prevention. Indicated for improving carotid luminal diameter in patients with neurological symptoms and >50% stenosis or asymptomatic patients with >80% stenosis (vessel diameters 4.8–9.0 mm) who are at high risk for adverse events from carotid endarterectomy. Sold to hospitals and vascular intervention centers performing carotid artery stenting procedures.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Patrick Muck serves as global co-principal investigator for CGUARDIANS III pivotal study evaluating SwitchGuard Neuro Protection System for TCAR procedures. Good Samaritan Hospital part of TriHealth System.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Patrick Geraghty serves as global co-principal investigator for CGUARDIANS III pivotal study. Academic medical center partnership for clinical research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. D. Christopher Metzger led C-GUARDIANS pivotal trial as principal investigator at OhioHealth Riverside Methodist Hospital, Columbus, Ohio.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medtronic offers the Mo.Ma Ultra proximal embolic protection device and broader vascular intervention portfolio referenced as a compatible accessory for CGuard procedures, and competes in carotid and neurovascular intervention as part of a much larger medtech portfolio.

2Terumo Corporation
TypeDirect peer
Description

Terumo's interventional systems division develops carotid and embolic protection products, positioning it as a direct peer in the vascular stent and embolic protection category where CGuard competes.

TypeBroad incumbent
Description

Stryker's Neurovascular division sells devices for stroke intervention (including mechanical thrombectomy and access products), serving overlapping hospital and interventional neurology customers as InspireMD's CGuard franchise.

TypeRegional player
Description

MicroPort is a global cardiovascular and endovascular device company with carotid and peripheral intervention products, representing an international peer in carotid and vascular stenting.

TypeBroad incumbent
Description

Edwards Lifesciences is a structural heart and vascular intervention incumbent; CCO Shane Gleason previously led U.S. transcatheter heart valves marketing at Edwards, and the company operates in adjacent vascular intervention segments.

6Abbott Laboratories
TypeBroad incumbent
Description

Abbott's vascular division sells the Roadsaver/CASPER carotid stent system (FDA-approved Nov 2024) and Emboshield NAV6 embolic protection device — both directly competitive with InspireMD's CGuard Prime and MicroNet technology in U.S. carotid stenting.

TypeRegional player
Description

Cordis, a Cardinal Health business, markets vascular access and intervention products including carotid stenting portfolios and is a former employer of InspireMD's CCO; it competes in the broader vascular intervention space.

TypeDirect peer
Description

Gore has historically been a meaningful player in carotid stent systems (e.g., Gore Carotid Stent) and competes with InspireMD in carotid artery stenting for high-surgical-risk patients.

TypeBroad incumbent
Description

Boston Scientific acquired Silk Road Medical (TCAR pioneer) for ~$1.18B in 2024 and competes broadly in vascular and carotid intervention; the recent CGUARDIANS III program targets the same TCAR segment that Boston Scientific now leads.

TypeEmerging player
Description

Penumbra is a neurovascular and vascular thrombectomy company addressing the broader stroke intervention market that includes carotid stenting, making it an adjacent peer with overlapping call points in neurovascular intervention.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InspireMD

Vascular Medical Devices (Carotid Stent Systems)inspiremd.com

InspireMD is a Miami-based medical device company that develops and commercializes the CGuard Prime carotid stent system, a MicroNet mesh-covered stent for stroke prevention, selling directly to hospitals and vascular specialists in the U.S. and Europe.

What InspireMD does

InspireMD is a U.S.-incorporated (Delaware) medical device company headquartered in Miami, Florida, with an Israeli R&D subsidiary, focused on stroke prevention through carotid artery stenting. Its commercial product is the CGuard Prime Carotid Stent System, a dual-layer device combining an inner self-expanding nitinol frame with an outer finely woven polyethylene terephthalate (PET) MicroNet mesh covering approximately 150-180 micrometer pore size, designed to prevent plaque prolapse and embolization during and after carotid artery stenting procedures. The system also incorporates SmartFit, a conformable open-cell stent design intended to adapt to a wide range of anatomies without tapered configurations.

The company's flagship product received FDA premarket approval in June 2025 and was launched in the U.S. market in July 2025, following international commercialization under CE MDR approval. The company is building a pipeline that includes the SwitchGuard Neuro Protection System for transcarotid artery revascularization (TCAR) procedures, currently in the CGUARDIANS III pivotal study, and is pursuing a PMA supplement for its 80 cm stent for the TCAR indication.

InspireMD generates revenue through direct enterprise field sales of its hardware products to hospitals and vascular intervention centers, with go-to-market supplemented by medical conference participation, peer-reviewed clinical publications, and physician education. Customers are vascular surgeons and interventional cardiologists treating patients with carotid artery stenosis who are at high risk for carotid endarterectomy. As of Q1 2026, the company reported revenue of $3.4 million, had raised over $189 million in cumulative funding across multiple private placements and warrant exercises since 2010, and was operating with 51-100 employees.

InspireMD firmographics

Firmographics
Name
InspireMD
Legal name
InspireMD, Inc.
Website
https://inspiremd.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
InspireMD is a Miami-based medical device company that develops and commercializes the CGuard Prime carotid stent system, a MicroNet mesh-covered stent for stroke prevention, selling directly to hospitals and vascular specialists in the U.S. and Europe.
Ownership category
akta.pro rank

InspireMD industry classification

Industry
Product category
Vascular Medical Devices (Carotid Stent Systems)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)

Keywords

  • Carotid stent systems
  • Stroke prevention devices
  • Embolic protection stents
  • Vascular medical devices
  • Endovascular intervention devices

Where InspireMD is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices1 record

Markets served

InspireMD business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. CGuard Prime Carotid Stent System Sales: Sale of FDA-approved CGuard Prime carotid stent system and delivery components to hospitals and vascular intervention centers. Revenue generated from product sales to healthcare providers performing carotid artery stenting procedures. Q4 2025 revenue of $3.1M with 62% year-over-year increase driven by U.S. launch and international expansion.
  2. International Product Sales: Revenue from international markets where CGuard has CE MDR approval. CGuard EPS indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

InspireMD product offering

Product offering

Core offering

InspireMD develops and commercializes the CGuard Prime Carotid Stent System, a dual-layer carotid stent with proprietary MicroNet mesh technology (woven PET outer layer with ~150-180 μm pore size) over a SmartFit nitinol frame, designed to prevent plaque prolapse and embolization during carotid artery stenting procedures for stroke prevention. The product is sold to hospitals and vascular intervention centers for use in patients at high risk for adverse events from carotid endarterectomy.

Product overview

InspireMD is a medical device company focused on stroke prevention through carotid artery stenting. The company offers a unified product portfolio centered on the CGuard Prime Carotid Stent System, which incorporates the proprietary MicroNet mesh technology for embolic protection. The flagship product is a dual-layer stent combining SmartFit nitinol frame technology with MicroNet mesh covering. Additional pipeline offerings include the SwitchGuard Neuro Protection System for TCAR procedures, which is currently in clinical development.

Differentiator

Problem solved

Functional benefit

Brands

  • CGuard: Next-generation carotid stenting system featuring a unique dual-layer design with a finely woven MicroNet mesh covering for stroke prevention
  • CGuard Prime
  • SwitchGuard
  • MicroNet
  • SmartFit

Products and services

  • CGuard Prime Carotid Stent System Dual-layer carotid stent system combining a SmartFit self-expanding nitinol open-cell frame with a MicroNet polyethylene terephthalate (PET) mesh outer covering (~150-180 μm pore size) for stroke prevention. Indicated for improving carotid luminal diameter in patients with neurological symptoms and >50% stenosis or asymptomatic patients with >80% stenosis (vessel diameters 4.8–9.0 mm) who are at high risk for adverse events from carotid endarterectomy. Sold to hospitals and vascular intervention centers performing carotid artery stenting procedures.

Quantifiable outcome

  • 0.95% 30-day Death, Stroke, or MI rate - lowest of any pivotal carotid stenting study
  • +3 more outcomes

Companies that use InspireMD

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

InspireMD technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

InspireMD partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Good Samaritan Hospital (TriHealth System)coreStrategic or Co-development PartnerDr. Patrick Muck serves as global co-principal investigator for CGUARDIANS III pivotal study evaluating SwitchGuard Neuro Protection System for TCAR procedures. Good Samaritan Hospital part of TriHealth System.
  • Washington University School of MedicinecoreStrategic or Co-development PartnerDr. Patrick Geraghty serves as global co-principal investigator for CGUARDIANS III pivotal study. Academic medical center partnership for clinical research.
  • OhioHealth Riverside Methodist HospitalcoreStrategic or Co-development PartnerDr. D. Christopher Metzger led C-GUARDIANS pivotal trial as principal investigator at OhioHealth Riverside Methodist Hospital, Columbus, Ohio.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

InspireMD competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Medtronic offers the Mo.Ma Ultra proximal embolic protection device and broader vascular intervention portfolio referenced as a compatible accessory for CGuard procedures, and competes in carotid and neurovascular intervention as part of a much larger medtech portfolio.
  • Stryker (Neurovascular): Stryker's Neurovascular division sells devices for stroke intervention (including mechanical thrombectomy and access products), serving overlapping hospital and interventional neurology customers as InspireMD's CGuard franchise.
  • Edwards Lifesciences: Edwards Lifesciences is a structural heart and vascular intervention incumbent; CCO Shane Gleason previously led U.S. transcatheter heart valves marketing at Edwards, and the company operates in adjacent vascular intervention segments.
  • Abbott Laboratories: Abbott's vascular division sells the Roadsaver/CASPER carotid stent system (FDA-approved Nov 2024) and Emboshield NAV6 embolic protection device — both directly competitive with InspireMD's CGuard Prime and MicroNet technology in U.S. carotid stenting.
  • Boston Scientific: Boston Scientific acquired Silk Road Medical (TCAR pioneer) for ~$1.18B in 2024 and competes broadly in vascular and carotid intervention; the recent CGUARDIANS III program targets the same TCAR segment that Boston Scientific now leads.

Direct peers

  • Terumo Corporation: Terumo's interventional systems division develops carotid and embolic protection products, positioning it as a direct peer in the vascular stent and embolic protection category where CGuard competes.
  • W. L. Gore & Associates: Gore has historically been a meaningful player in carotid stent systems (e.g., Gore Carotid Stent) and competes with InspireMD in carotid artery stenting for high-surgical-risk patients.

Regional players

  • MicroPort Scientific Corporation: MicroPort is a global cardiovascular and endovascular device company with carotid and peripheral intervention products, representing an international peer in carotid and vascular stenting.
  • Cardinal Health (Cordis): Cordis, a Cardinal Health business, markets vascular access and intervention products including carotid stenting portfolios and is a former employer of InspireMD's CCO; it competes in the broader vascular intervention space.

Emerging players

  • Penumbra, Inc. Penumbra is a neurovascular and vascular thrombectomy company addressing the broader stroke intervention market that includes carotid stenting, making it an adjacent peer with overlapping call points in neurovascular intervention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

InspireMD social profiles

Digital presence

InspireMD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InspireMD leadership team

Management profile

Number of profiles

Profiles13 records

InspireMD funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InspireMD M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InspireMD

What does InspireMD do?

InspireMD develops and commercializes the CGuard Prime Carotid Stent System, a dual-layer carotid stent with proprietary MicroNet mesh technology (woven PET outer layer with ~150-180 μm pore size) over a SmartFit nitinol frame, designed to prevent plaque prolapse and embolization during carotid artery stenting procedures for stroke prevention. The product is sold to hospitals and vascular intervention centers for use in patients at high risk for adverse events from carotid endarterectomy.

Is InspireMD a public or private company?

InspireMD is a public company. It is classified as public and is currently operating.

When was InspireMD founded?

InspireMD was founded in 2005. It employs 101 to 250 people.

Where is InspireMD based?

InspireMD is headquartered in Miami, United States, in the North America region.

How does InspireMD make money?

Two revenue lines are on record. CGuard Prime Carotid Stent System Sales are the primary driver. The others are international Product Sales.

Who are InspireMD's main competitors?

Broad incumbents on record are Medtronic, Stryker (Neurovascular), Edwards Lifesciences, Abbott Laboratories and Boston Scientific. Direct peers are Terumo Corporation and W. L. Gore & Associates. Regional players are MicroPort Scientific Corporation and Cardinal Health (Cordis). Penumbra, Inc. is listed as an emerging player.

Does InspireMD have an API?

No public API is recorded for InspireMD.

What industry is InspireMD in?

InspireMD's product category is Vascular Medical Devices (Carotid Stent Systems). Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingInspireMD Hosts Expert Webinar on Carotid Stenting and CGuard Prime PlatformInspireMD will host a webinar on its CGuard Prime carotid stent platform on November 19, 2026, at 4:30 p.m. EST. Six physician experts will discuss carotid artery disease management and the platform's clinical benefits.TradingViewInspireMD Prices $37.5 Million Public Offering of Stock and WarrantsInspireMD entered an underwriting agreement with Lake Street Capital Markets to raise approximately $37.5 million in a public offering of common stock and warrants. The company plans to use the net proceeds for operations, including research and development, sales and marketing, working capital, and general corporate purposes.Business & FinancialInspiremd Announces Pricing Of $37.5 Million Public OfferingInspireMD priced a $37.5 million public offering of common stock and pre-funded warrants, with a 30-day over-allotment option. The offering is expected to close on November 16, 2026, and proceeds will be used for research, development, sales, marketing, and working capital.The future of tradingInspireMD Prices $37.5 Million Public OfferingInspireMD priced a $37.5 million underwritten public offering on November 13, 2026, comprising 7,342,308 common shares and pre-funded warrants to purchase 50,350,000 shares. Closing is expected on or about November 16, 2026, with net proceeds intended for research, development, sales, marketing, and working capital.YahooInspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens US ...InspireMD reported Q3 2026 revenue of $2.2 million, down 11% year over year, with a net loss of $9.8 million. The FDA approved CGuard Prime for TCAR procedures, expanding the US addressable market by about 40,000 annual procedures. The company expects reentry of the recalled delivery system in the first half of 2027.MarketScreenerInspireMD Recieves FDA Approval for Stroke-Reduction ProductInspireMD received FDA approval for CGuard Prime for transcarotid arterial revascularization procedures in the U.S. The approval is expected to roughly double the company's total addressable market, with over 35,000 procedures annually. The company expects to start U.S. sales in the current fourth quarter.Investing.comEarnings call transcript: InspireMD posts Q3 2026 beat but shares fallInspireMD reported Q3 2026 revenue of $2.2 million, down 11% year-over-year, and a net loss of $0.12 per share, beating the $0.15 loss estimate. The company also won FDA approval for CGuard Prime for TCAR procedures, but shares fell 16% after hours on margin and dilution concerns.MarketWatchInspireMD Recieves FDA Approval for Stroke-Reduction ProductInspireMD received FDA approval for CGuard Prime for transcarotid arterial revascularization procedures in the U.S., expected to double its addressable market. The device treats carotid artery stenosis, with over 35,000 procedures annually, and U.S. sales are expected in the current fourth quarter.Quiver QuantitativeInspireMD Reports $2.24 Million Q3 Revenue and FDA TCAR Approval | NSPR Stock NewsInspireMD reported Q3 2026 revenue of $2.242 million, down 11.1% year-over-year, and a net loss of $9.762 million. The company received FDA approval for CGuard Prime for transcarotid arterial revascularization and expects U.S. sales in Q4 2026.YahooInspireMD, Inc. (NSPR) Reports Q3 Loss, Beats Revenue EstimatesInspireMD reported a Q3 loss of $0.11 per share, beating the consensus estimate of $0.15, and posted revenue of $2.24 million, up 19.26% from the estimate. The company has surpassed consensus EPS estimates four times in the last four quarters. Management's commentary on the earnings call will influence near-term stock movement.